US-based small molecule discovery company Receptos secured $10.8m out of a planned $50m series B round last Friday, bringing its total funding to about $43.5m.

Investors in the round have not been officially disclosed but signatories for the filing include Receptos board members who are also members of Lilly Ventures, the corporate venturing fund for pharmaceutical conglomerate Eli Lilly, and venture capital firms Arch Venture Partners and Flagship Ventures, as well as Amir Nashat, principal at VC firm Polaris Venture…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?